Linifanib

Summary

Linifanib (CHEMBL223360) is a phase-3 clinical-stage small-molecule antineoplastic agent targeting PDGFRB, KIT, and CSF1R; indicated across 10 conditions including hepatocellular carcinoma and renal cell carcinoma; with CIViC clinical evidence for 4 variant-indication associations (e.g. FLT3 D593del in cancer).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 11 (PDGFRB, KIT, CSF1R…)
• Indications: 10 conditions
• Clinical trials: 19
• Precision-oncology evidence (CIViC): 4 variant–indication associations
• Chemistry: 375.4 Da · C21H18FN5O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL223360
Name	Linifanib
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11485656
ChEBI	CHEBI:91435
Molecular formula	C21H18FN5O
Molecular weight	375.4
InChIKey	MPVGZUGXCQEXTM-UHFFFAOYSA-N

SMILES: CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N

IUPAC name: 1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea

ChEBI definition: A member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 2-fluoro-5-methylphenyl group, while the other is substituted by a p-(3-amino-1H-indazol-4-yl)phenyl group. It is a potent, selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinases.

Pharmacological roles (ChEBI): antineoplastic agent, EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, angiogenesis inhibitor.

Also known as: A-741439, ABT-869, AL-39324, Linifanib, RG-3635, SID103904340, LINIFANIB, SID137275904, LINIFANIB (ABT-869), LinifanibÊ, Linifanib (ABT-869), LinifanibÂ

Patent coverage: 1,533 distinct patent families (3,925 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,792 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PDGFRB	platelet derived growth factor receptor beta	Inhibition	7.18	2.3%	P09619
KIT	KIT proto-oncogene, receptor tyrosine kinase	Inhibition	7.85	0.5%	P10721
CSF1R	colony stimulating factor 1 receptor	Inhibition	8.52	0%	P07333
FLT3	fms related receptor tyrosine kinase 3	Inhibition	8.4	0.9%	P36888
FLT1	fms related receptor tyrosine kinase 1	Inhibition	8.52	0.1%	P17948
KDR	kinase insert domain receptor	Inhibition	8.4	1.1%	P35968
FLT4	fms related receptor tyrosine kinase 4	Inhibition	6.72	0.2%	P35916
TEK	TEK receptor tyrosine kinase	Inhibition	6.77	0%	Q02763
CDK19	cyclin dependent kinase 19	Inhibition	7.92	0.1%	Q9BWU1
CDK8	cyclin dependent kinase 8	Inhibition	8.16	6.5%	P49336
RET	ret proto-oncogene	Inhibition	5.72	0.4%	P07949

Broader ChEMBL bioactivity targets: 135 (assay-derived). Sample: Homeodomain-interacting protein kinase 4, Cyclin-dependent kinase 13, Macrophage colony-stimulating factor 1 receptor, Tyrosine-protein kinase ABL1, Protein deacetylase HDAC6, Vascular endothelial growth factor receptor 1, Platelet-derived growth factor receptor beta, Mast/stem cell growth factor receptor Kit, Vascular endothelial growth factor receptor 3, Receptor-type tyrosine-protein kinase FLT3.

Bioactivity

ChEMBL activities: 311 potent at pChembl ≥ 5 of 314 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FLT3	9.2	Kd	0.63	nM	CHEMBL_ACT_2907377
FLT3	9.2	Kd	0.63	nM	CHEMBL_ACT_7583484
CDK8	9	Ki	1	nM	CHEMBL_ACT_9644434
FLT3	8.89	Kd	1.3	nM	CHEMBL_ACT_7583488
KIT	8.77	Kd	1.7	nM	CHEMBL_ACT_2897021
KIT	8.77	Kd	1.7	nM	CHEMBL_ACT_7583337
PDGFRB	8.72	Kd	1.9	nM	CHEMBL_ACT_2899063
KIT	8.72	Kd	1.9	nM	CHEMBL_ACT_7583336
PDGFRB	8.72	Kd	1.9	nM	CHEMBL_ACT_7583422
KIT	8.7	Kd	2	nM	CHEMBL_ACT_2895921
KIT	8.7	Kd	2	nM	CHEMBL_ACT_6220441
KIT	8.7	Kd	2	nM	CHEMBL_ACT_7583332
KDR	8.64	IC50	2.3	nM	CHEMBL_ACT_14746904
FLT3	8.59	Kd	2.6	nM	CHEMBL_ACT_2890843
FLT3	8.59	Kd	2.6	nM	CHEMBL_ACT_7583489
FLT3	8.57	Kd	2.7	nM	CHEMBL_ACT_2907415
FLT3	8.57	Kd	2.7	nM	CHEMBL_ACT_7583485
FLT1	8.52	IC50	3	nM	CHEMBL_ACT_1826430
CSF1R	8.52	IC50	3	nM	CHEMBL_ACT_1826433
FLT1	8.52	IC50	3	nM	CHEMBL_ACT_18568749
CSF1R	8.52	IC50	3	nM	CHEMBL_ACT_18568752
FLT1	8.52	IC50	3	nM	CHEMBL_ACT_26132432
CSF1R	8.47	Kd	3.4	nM	CHEMBL_ACT_2902370
CSF1R	8.47	Kd	3.4	nM	CHEMBL_ACT_7583545
KIT	8.42	Kd	3.8	nM	CHEMBL_ACT_2896945
KIT	8.42	Kd	3.8	nM	CHEMBL_ACT_7583338
KDR	8.4	IC50	4	nM	CHEMBL_ACT_1826115
KDR	8.4	IC50	4	nM	CHEMBL_ACT_1826380
KDR	8.4	IC50	4	nM	CHEMBL_ACT_18568745
FLT3	8.4	IC50	4	nM	CHEMBL_ACT_18568746

Target pathways

Aggregated over 11 target gene(s): PDGFRB, KIT, CSF1R, FLT3, FLT1, KDR, FLT4, TEK, CDK19, CDK8, RET.

Top Reactome pathways

109 total, by targets touching each:

Pathway	Targets	Genes
RAF/MAP kinase cascade	5	FLT3, KIT, PDGFRB, RET, TEK
PIP3 activates AKT signaling	3	FLT3, KIT, PDGFRB
Developmental Biology	3	CDK19, CDK8, KIT
Signal Transduction	3	CDK8, KIT, TEK
Disease	3	CDK19, CDK8, KIT
VEGF binds to VEGFR leading to receptor dimerization	3	FLT1, FLT4, KDR
Constitutive Signaling by Aberrant PI3K in Cancer	3	FLT3, KIT, PDGFRB
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	3	FLT3, KIT, PDGFRB
Metabolism	2	CDK19, CDK8
Neuropilin interactions with VEGF and VEGFR	2	FLT1, KDR
PPARA activates gene expression	2	CDK19, CDK8
Generic Transcription Pathway	2	CDK8, KIT
Transcriptional regulation of white adipocyte differentiation	2	CDK19, CDK8
Regulation of lipid metabolism by PPARalpha	2	CDK19, CDK8
Metabolism of lipids	2	CDK19, CDK8
Diseases of signal transduction by growth factor receptors and second messengers	2	CDK8, KIT
Infectious disease	2	CDK19, CDK8
MAPK family signaling cascades	2	KIT, TEK
MAPK1/MAPK3 signaling	2	KIT, TEK
RNA Polymerase II Transcription	2	CDK8, KIT
Gene expression (Transcription)	2	CDK8, KIT
Respiratory Syncytial Virus Infection Pathway	2	CDK19, CDK8
Viral Infection Pathways	2	CDK19, CDK8
RSV-host interactions	2	CDK19, CDK8
Adipogenesis	2	CDK19, CDK8
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	2	FLT4, KDR
Hemostasis	1	TEK
PI3K Cascade	1	FLT3
Signaling by SCF-KIT	1	KIT
Regulation of KIT signaling	1	KIT

Dominant GO biological processes

GO term	Targets
protein phosphorylation	11
cell surface receptor protein tyrosine kinase signaling pathway	9
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	8
positive regulation of cell population proliferation	7
positive regulation of cell migration	7
protein autophosphorylation	7
cell migration	7
positive regulation of MAPK cascade	7
peptidyl-tyrosine phosphorylation	6
angiogenesis	5
positive regulation of ERK1 and ERK2 cascade	5
hemopoiesis	5
signal transduction	4
negative regulation of apoptotic process	4
vascular endothelial growth factor signaling pathway	4

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
age-related macular degeneration	2	MONDO:0005150	EFO:0001365
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
colorectal adenocarcinoma	2	MONDO:0005008	EFO:0000365
rectal cancer	2	MONDO:0006519	EFO:1000657
breast neoplasm	2	MONDO:0021100	MONDO:0007254
colonic neoplasm	2	MONDO:0005401	MONDO:0021063
neoplasm	1	MONDO:0005070	EFO:0000616
endometriosis	1	MONDO:0005133	EFO:0001065

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
PHASE1	10
PHASE2	7
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01009593	PHASE3	TERMINATED	Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
NCT00486538	PHASE2	COMPLETED	Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib
NCT00517790	PHASE2	COMPLETED	Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT00517920	PHASE2	COMPLETED	Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
NCT00645177	PHASE2	COMPLETED	Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer
NCT00707889	PHASE2	COMPLETED	Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
NCT00716534	PHASE2	COMPLETED	Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT01365910	PHASE2	TERMINATED	Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
NCT03481842	PHASE1/PHASE2	WITHDRAWN	Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
NCT00718380	PHASE1	COMPLETED	A Phase 1 Study of ABT-869 in Subjects With Solid Tumors
NCT00733187	PHASE1	COMPLETED	Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869
NCT00754104	PHASE1	WITHDRAWN	Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors
NCT01114191	PHASE1	COMPLETED	A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)
NCT01225302	PHASE1	COMPLETED	A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)
NCT01286974	PHASE1	TERMINATED	A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.
NCT01381341	PHASE1	COMPLETED	To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.
NCT01401933	PHASE1	COMPLETED	Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
NCT01413893	PHASE1	COMPLETED	An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors
NCT01506934	PHASE1	TERMINATED	A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Clinical evidence (CIViC)

Variant × indication × effect (4 predictive associations from 4 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
FLT3 D593del	Cancer	Sensitivity/Response	Sorafenib + Sunitinib + Quizartinib + Linifanib	CIViC D	EID11094
FLT3 D835Y	Cancer	Sensitivity/Response	Quizartinib + KW2449 + R406 + Ponatinib + AG1295 + Sorafenib + Sunitinib + AGS324 + Linifanib	CIViC D	EID11086
FLT3 ITD	Cancer	Sensitivity/Response	FLT3 Tyrosine Kinase Inhibitor TTT-3002 + R406 + Ponatinib + Crenolanib + KW2449 + Sorafenib + Sunitinib + Quizartinib + Linifanib + AGS324 + AG1295 + Lestaurtinib + Midostaurin	CIViC D	EID11084
FLT3 Overexpression AND FLT3LG Expression	Cancer	Sensitivity/Response	Quizartinib + Linifanib + Lestaurtinib + Midostaurin + Ponatinib + FLT3 Tyrosine Kinase Inhibitor TTT-3002 + Sunitinib	CIViC D	EID11088

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

272 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CDK8, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
Crizotinib	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CDK8, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CDK8, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
QUIZARTINIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CDK8, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
SORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CDK8, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
DORAMAPIMOD	ChEMBL	Phase 2	CDK19, CDK8, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
FORETINIB	ChEMBL	Phase 2	CDK19, CDK8, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
Selumetinib	PubChem	Approved	CDK19, CDK8, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
AXITINIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
FEDRATINIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
GEFITINIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CDK8, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, RET, TEK
MIDOSTAURIN	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
VANDETANIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
LESTAURTINIB	ChEMBL	Phase 3	CDK8, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
RAF-265	ChEMBL	Phase 2	CDK19, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
TOZASERTIB	ChEMBL	Phase 2	CDK19, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
PONATINIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CDK8, CSF1R, FLT1, FLT3, KDR, KIT, PDGFRB, RET
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
SUNITINIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
NINTEDANIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
CEDIRANIB	ChEMBL	Phase 3	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
VATALANIB	ChEMBL	Phase 3	CDK19, CDK8, CSF1R, FLT1, FLT4, KDR, KIT, PDGFRB, RET
DEFOSBARASERTIB	ChEMBL	Phase 2	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
ILORASERTIB	ChEMBL	Phase 2	CDK8, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
R-406	ChEMBL	Phase 2	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
ERLOTINIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
TIVOZANIB	ChEMBL	Phase 4 (approved)	FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
BRIVANIB	ChEMBL	Phase 3	CSF1R, FLT1, FLT4, KDR, KIT, PDGFRB, RET, TEK
DOVITINIB	ChEMBL	Phase 3	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
MOTESANIB	ChEMBL	Phase 3	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
SEMAXANIB	ChEMBL	Phase 3	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
CENISERTIB	ChEMBL	Phase 2	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
REBASTINIB	ChEMBL	Phase 2	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, RET, TEK
SU-014813	ChEMBL	Phase 2	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
Idelalisib	PubChem	Approved	CSF1R, FLT1, FLT3, FLT4, KIT, PDGFRB, RET, TEK
BOSUTINIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CSF1R, FLT3, KIT, PDGFRB, RET, TEK
NILOTINIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CSF1R, FLT3, KIT, PDGFRB, RET, TEK
PEXIDARTINIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CSF1R, FLT1, FLT3, KDR, KIT, PDGFRB
CABOZANTINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT3, FLT4, KDR, KIT, RET, TEK
DASATINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT1, FLT3, KDR, KIT, PDGFRB, RET
ENTRECTINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, RET
INFIGRATINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT3, FLT4, KDR, KIT, RET, TEK
CEP-32496	ChEMBL	Phase 2	CSF1R, FLT1, FLT3, KDR, KIT, PDGFRB, RET
OSI-632	ChEMBL	Phase 2	FLT1, FLT3, FLT4, KDR, PDGFRB, RET, TEK
TANDUTINIB	ChEMBL	Phase 2	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB
IMATINIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CSF1R, FLT3, KDR, KIT, PDGFRB
BRIGATINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, FLT4, KDR, KIT, RET
LENVATINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR, KIT, PDGFRB, RET
CANERTINIB	ChEMBL	Phase 3	FLT1, FLT3, KDR, KIT, PDGFRB, RET
BFH-772	ChEMBL	Phase 2	FLT1, FLT4, KDR, KIT, PDGFRB, RET
CEP-11981	ChEMBL	Phase 2	CSF1R, FLT1, FLT3, KDR, RET, TEK
MK-2461	ChEMBL	Phase 2	FLT1, FLT3, FLT4, KDR, PDGFRB, RET
NERATINIB	ChEMBL + PubChem	Phase 4 (approved)	CDK19, CSF1R, FLT3, KDR, TEK
ALVOCIDIB	ChEMBL	Phase 3	CDK19, CDK8, CSF1R, FLT3, KIT
BARASERTIB	ChEMBL	Phase 3	FLT3, KDR, KIT, PDGFRB, RET
ORANTINIB	ChEMBL	Phase 3	FLT1, FLT3, KDR, PDGFRB, RET
SARACATINIB	ChEMBL	Phase 3	FLT3, KDR, KIT, PDGFRB, RET
AT-9283	ChEMBL	Phase 2	FLT1, FLT3, FLT4, KDR, RET
DANUSERTIB	ChEMBL	Phase 2	FLT3, FLT4, KDR, KIT, RET
ENMD-2076	ChEMBL	Phase 2	CSF1R, FLT3, KDR, KIT, RET